Covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain.

Covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain.
Introduction: At the time of writing the US stock market is set for its 70th record close of the year. Older market watchers will know that a wall of worry is what
Introduction: At the time of writing the US stock market is set for its 70th record close of the year. Older market watchers will know that a wall of worry is what
The Top 20 For 2022: Of course, at this time of the year, everyone and their mother deliver their list for the winners of the New Year, as I have in
The Top 20 For 2022: Of course, at this time of the year, everyone and their mother deliver their list for the winners of the New Year, as I have in
The Top 20 For 2022: Of course, at this time of the year, everyone and their mother deliver their list for the winners of the New Year, as I have
OKYO to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.
London and Boston, MA, 29 June 2021 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory
Prospectus Publication Announcement
OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain